Digital biomarkers for COPD
What patients report as their central problem is that breathlessness limits what they can do, which lung function tests capture poorly.
.png)
Chronic obstructive pulmonary disease has an unusually direct relationship with digital measurement, because the outcome that matters most to patients is one that clinic testing captures poorly. Lung function tests measure airflow limitation. What people with COPD report as their central problem is that breathlessness limits what they can do, and daily physical activity is the continuous expression of that limitation.
The measures used in this condition therefore span two domains. Activity measures, particularly daily step count and walking bout structure, describe functional status in real life. Respiratory measures, including cough frequency, oxygen saturation, breathing rate and home spirometry, describe the state of the lungs and airways.
Physical activity in COPD has a stronger claim on attention than in most conditions. It is among the better predictors of hospitalisation and mortality in this population, it declines early in the disease course, and it responds to pulmonary rehabilitation. Unlike many digital measures searching for a use case, activity measurement in COPD arrived with an established clinical rationale already in place.
Digital biomarkers used in COPD research
How these measures are used
The most developed use is measuring the effect of pulmonary rehabilitation and other interventions on daily activity, an area with published minimal important difference estimates, which is rare among digital measures and makes trial interpretation considerably easier.
The second use is exacerbation work. Respiratory measures respond within days, so continuous monitoring can identify onset earlier than a scheduled visit and can quantify how long recovery takes, which conventional endpoints capture poorly. Activity typically falls sharply during an exacerbation and often does not fully return, and that incomplete recovery is itself an outcome worth measuring.
Cough frequency occupies a distinct position. In the registered trial literature it is used almost exclusively as a primary endpoint rather than as a supporting measure, which reflects its clinical face validity in respiratory disease. These measures are reported alongside a validated respiratory questionnaire covering symptom burden and daily impact.
What the evidence supports today
COPD has one of the better evidence positions for digital activity measurement. Daily step count has established prognostic associations in this population and, importantly, published estimates of the change that constitutes a meaningful difference, which most digital measures lack entirely. Randomised trials have shown that activity in COPD can be increased by intervention, which establishes it as a responsive endpoint rather than only a descriptive one.
Walking bout structure has been technically validated in COPD through the Mobilise-D consortium, which included the condition in its multi cohort validation programme, and construct validity work in this population has followed.
The weaker areas are the same as in the wider respiratory domain. Wrist based oxygen saturation is less accurate than fingertip oximetry and is generally not a cleared clinical measurement. Home spirometry is more variable than supervised testing. Neither undermines the activity evidence, but studies should not present all of these measures as though they carried equal weight.
Common questions
Why is physical activity such an important measure in COPD?
Because it predicts hospitalisation and mortality in this population, declines early in the disease, and responds to pulmonary rehabilitation. It also reflects what patients describe as their main problem, which is that breathlessness limits what they can do, more directly than a lung function test does.
Is there a meaningful change threshold for step count in COPD?
Yes, which distinguishes this condition from most. Research has estimated a minimal important difference in daily steps for people with COPD, giving trials a basis for interpreting whether an observed change matters rather than only whether it is statistically detectable.
Can digital measures detect an exacerbation early?
Respiratory measures such as cough frequency, breathing rate and oxygen saturation shift within days of onset, and activity typically falls. Research supports detection ahead of a scheduled visit. Turning that into a reliable individual level alarm, with an acceptable false alarm rate, is still work in progress.
Which devices are used for these measures in COPD studies?
Research grade accelerometers where activity accuracy matters most, since walking is slow and step detection is harder at low speeds. Consumer wearables where adherence and duration matter more. Cough requires dedicated acoustic monitoring hardware, and lung function requires a connected spirometer.
Run a study on these measures
WeGuide captures wearable data and patient reported outcomes in one platform, from screening through to analysis.
